Shareholder Alert: The Ademi Firm investigates whether Metsera Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Sept. 22, 2025 /PRNewswire/ -- The Ademi Firm is investigating Metsera (Nasdaq: MTSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

Shareholders of Metsera will receive $47.50 per share in a transaction with an enterprise value of approximately $4.9 billion. Metsera insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Metsera by imposing a significant penalty if Metsera accepts a competing bid. We are investigating the conduct of the Metsera board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

SOURCE Ademi LLP